ASH21

Patrick DalyMyeloma | November 14, 2022
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
Sabrina AhleMantle Cell Lymphoma | February 1, 2023
A recent study of brexu-cel supports its use for the treatment of MCL.
Ariel DeMaioAggressive B-Cell Lymphoma | February 1, 2023
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Advertisement
Brandon MayMyeloma | November 14, 2022
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Sabrina AhleChronic Lymphocytic Leukemia | February 2, 2023
Frontline treatment of ibrutinib plus venetoclax induced deep responses in patients with previously untreated CLL.
Brandon MayAggressive B-Cell Lymphoma | November 14, 2022
Circulating tumor DNA accurately reflects tumor burden and may serve as a useful clinical biomarker for risk and outcome in ...
Advertisement
Naval Daver, MDAcute Myeloid Leukemia | February 2, 2023
According to results presented at ASH 2021, the triplet combination of magrolimab plus azacitidine and venetoclax was safe.
Jacob Laubach, MD, MPPMyeloma | November 14, 2022
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Jacob Laubach, MD, MPPMyeloma | November 14, 2022
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Naval Daver, MDAcute Myeloid Leukemia | February 2, 2023
Dr. Daver shares results from a phase I/II study evaluating the addition of the anti-CD47 antibody magrolimab.
Sabrina AhleAcute Myeloid Leukemia | February 2, 2023
Induction and consolidation therapy with the combination induced responses in 98% of patients with newly diagnosed AML.
Brandon MayAcute Myeloid Leukemia | February 2, 2023
Three-quarters of evaluable patients experienced complete cytogenetic complete response.
Leah LawrenceMyeloproliferative Neoplasms | November 15, 2022
Researchers shared a new single-cell multi-omic analysis of the genetic, cellular, and molecular landscape of TP53-driven.
Noopur Raje, MDMyeloma | January 31, 2023
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Noopur Raje, MDMyeloma | November 14, 2022
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
Leah LawrenceAggressive B-Cell Lymphoma | November 14, 2022
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Ariel DeMaioChronic Lymphocytic Leukemia | February 2, 2023
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
Advertisement
Advertisement